New data demonstrates robust efficacy of Vyepti® in otherwise difficult-to-treat patients with severe migraine

H. Lundbeck A/S Denmark

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated statistically significant reductions compared to placebo in mean monthly migraine days (MMDs) within the first 4 weeks, in patients with chronic migraine and medication-overuse headache who also received standardized patient educationPatients treated with eptinezumab reported rapid reductions in pain severity by Week 2, compared to placebo, alongside a significant reduction in the use of acute migraine medicationImprovements were observed across patient-reported outcomes, including reductions in headache-related burden, migraine-related disability, work productivity loss, and activity impairment  

[phone]

[phone]

Palle Holm Olesen

Vice President, Investor Relations

[e-mail]

[phone]

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has approximately 5,700 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

References:

Kristoffersen ES, et al. J Neurol Neurosurg Psychiatry. 2015;86(5):505-12Jensen RH, et al. ePresentation at EAN 2025Katsarava Z, et al.  Curr Pain Headache Rep 2012; 16: 86–92Lipton RB, et al.  J Neurol 2023; 270: 5692–5710Da Silva AN, Lake AE 3rd. Headache. 2014;54:211–7Tepper SJ, et al. ePresentation at EAN 2025Villalón CM. Pharmacol Ther. 2009;124(3):309-323.Steiner TJ, et al. J Headache Pain. 2018;19(1):17.Gustavsson A, et al. Eur Neuropsychopharmacol. 2011;21(10):718-79.Lipton RB, et al. J Neurol. 2023; 270, 5692–5710.Jensen RH, et al. Front. Neurol. 2023; 14:1114654.Ashina M, et al. Cephalalgia. 2020;40(3):241-254.Lipton RB, et al. Neurology. 2020;94(13):e1365-e1377.

CONTACT:

H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
[phone]
[e-mail]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/h--lundbeck-a-s/r/new-data-demonstrates-robust-efficacy-of-vyepti---eptinezumab--in-otherwise-difficult-to-treat-patie,c4166991

The following files are available for download:

https://mb.cision.com/Main/18215/4166991/3515992.pdf

EAN RESOLUTION Press Release_Final

View original content:https://www.prnewswire.co.uk/news-releases/new-data-demonstrates-robust-efficacy-of-vyepti-eptinezumab-in-otherwise-difficult-to-treat-patients-with-severe-migraine-302487653.html

@ prnewswire.co.uk